Philadelphia, Pa., USA - November 5, 2015, Philadelphia, Pa., USA - Rosetta Genomics Ltd., a molecular diagnostics company, appoints Maria Fe Paz as a medical affairs consultant in the role of interim chief medical officer.
Article continues below
Plans are Dr. Fe Paz to transition to Chief Medical Officer of Rosetta Genomics upon receipt of a valid work visa that supports her planned relocation to the U.S.
Dr. Paz is an accomplished chief medical officer with nearly 15 years’ of experience in the
pharmaceutical and biomedical industry, with demonstrated achievements in molecular
diagnostics, translational and precision medicine.
Dr. Paz joins Rosetta Genomics from Labceutics and the Diaceutics Group, where she was the
Founder-President and Chief Medical Officer, respectively.
Prior to joining Diaceutics and founding Labceutics, Dr. Paz was head of translational medicine and scientific development at Zeltia SA., a biopharmaceutical company, where she forged important relationships with international labs and hospitals, and gained over 10 years’ experience establishing and managing laboratories for molecular diagnostics and precision medicine.
In Dr. Paz’s earlier experience, she founded and served as the Scientific-Medical Consultant for Epicure Molecular, where she was responsible for advising on the pharmacogenetics and molecular diagnostic strategies for drug and biomarker development to pharmaceutical companies.
Dr. Paz was the Head of the Epigenetics Unit at the Spanish National Cardiovascular Centre (CNIC), and was the founder and director of Molecular and Genetic Diagnostics Laboratories in Hospital de Madrid. She began her career as a principal scientist at the Spanish Biotechnology Centre (CSIC).
Dr. Paz received her B.A. in Molecular Biology and M.D. at the Universidad Autónoma de Madrid, and holds a Ph.D. from the Spanish National Cancer Center. She was a Predoctoral Fellow at the Sydney Kimmel Cancer Center at Johns Hopkins University and a Postdoctoral Fellow at the Spanish National Cancer Centre. ■